We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




A Liquid Biopsy for Diagnosis of Pediatric High-Grade Glioma

By LabMedica International staff writers
Posted on 04 Nov 2020
A liquid biopsy approach that detects cell-free tumor DNA (cf-tDNA) in samples of cerebrospinal fluid has been used to diagnose pediatric high-grade glioma (pHGG), a rare but usually fatal childhood brain cancer.

Tumors release cell-free tumor DNA (cf-tDNA) into cerebrospinal fluid (CSF), allowing for potential detection of tumor-associated mutations by CSF sampling. More...
Up to now, liquid biopsy has been particularly challenging for brain tumors because mutant DNA is shed into body fluids at much lower levels than any other types of tumors.

Investigators at the University of Michigan (Ann Arbor, USA) hypothesized that direct, electronic analysis of cf-tDNA with a handheld analytical platform - the Oxford Nanopore Technologies (Oxford, United Kingdom) MinION - could quantify patient-specific CSF cf-tDNA variant allele fraction (VAF) with improved speed and limit of detection compared with established methods.

Nanopore sequencing is a unique, scalable technology that enables direct, real-time analysis of DNA or RNA fragments. It works by monitoring changes to an electrical current as nucleic acids are passed through a protein nanopore. The resulting signal is decoded to provide the specific DNA or RNA sequence. Using nanopore sequencing, a single molecule of DNA or RNA can be sequenced without the need for PCR amplification or chemical labeling of the sample.

To prove their hypothesis, the investigators performed ultra-short fragment (100–200 base pair) PCR amplification of cf-tDNA for clinically actionable alterations in CSF and tumor samples from 12 patients with pHGG alongside six CSF samples from nontumor control patients. PCR products underwent rapid amplicon-based sequencing on the Oxford Nanopore MinION instrument with quantification of VAF. Additional comparisons to next-generation sequencing (NGS) and droplet digital PCR (ddPCR) were performed.

Results revealed that the Nanopore instrument, which requires significantly smaller amounts of spinal fluid than other sequencing methods, demonstrated 85% sensitivity and 100% specificity in CSF samples (n = 127 replicates) with 0.1 femtomole DNA limit of detection and 12-hour results, all of which compared favorably with NGS. Serial CSF cf-tDNA sequencing by Nanopore demonstrated correlation of radiological response on a clinical trial, with one patient showing dramatic multi-gene molecular response that predicted long-term clinical response.

The results obtained by this study confirmed that Nanopore sequencing of ultra-short pHGG CSF cf-tDNA fragments was feasible, efficient, and sensitive with low-input samples thus overcoming many of the barriers restricting wider use of CSF cf-tDNA diagnosis and monitoring.

"We knew from past research that the genetic sequences of these tumors, including information about the mutations that are driving them, can be found in the spinal fluid - but collecting it is not currently part of the standard of care," said senior author Dr. Carl Koschmann, a pediatric oncologist at the University of Michigan. "That is something we have been hoping to change."

"As caregivers, we are excited about the possibility of monitoring tumors without exposing patients to potential complications from invasive surgeries," said Dr. Koschmann. "This approach suggests we can rapidly and reliably detect key tumor-driving mutations in high-grade gliomas with very small samples - overcoming some of the barriers that were preventing the use of spinal cord fluid in diagnosing and monitoring these patients. And we are optimistic about incorporating this approach into clinical trial design for pediatric brain cancer, allowing us to track molecular response across multiple genes to better understand and predict clinical outcomes."

The study was published in the October 21, 2020, online edition of the journal Clinical Cancer Research.

Related Links:
University of Michigan
Oxford Nanopore Technologies



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.